REFERENCES
1. Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol 2018;15:617-38.
2. Chang W, Cerione RA, Antonyak MA. Extracellular vesicles and their roles in cancer progression. In: Robles-flores M, editor. Cancer Cell Signaling. New York: Springer US; 2021. pp. 143-70.
3. Ye Z, Chen W, Li G, Huang J, Lei J. Tissue-derived extracellular vesicles in cancer progression: mechanisms, roles, and potential applications. Cancer Metastasis Rev 2024;43:575-95.
4. Crow J, Samuel G, Godwin AK. Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy. Expert Rev Mol Diagn 2019;19:1079-88.
5. Trinidad CV, Tetlow AL, Bantis LE, Godwin AK. Reducing ovarian cancer mortality through early detection: approaches using circulating biomarkers. Cancer Prev Res 2020;13:241-52.
6. Hinestrosa JP, Kurzrock R, Lewis JM, et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Commun Med 2022;2:29.
7. Irmer B, Chandrabalan S, Maas L, Bleckmann A, Menck K. Extracellular vesicles in liquid biopsies as biomarkers for solid tumors. Cancers 2023;15:1307.
8. Yu D, Li Y, Wang M, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer 2022;21:56.
9. Zhou E, Li Y, Wu F, et al. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine 2021;67:103365.
10. Rayamajhi S, Sipes J, Tetlow AL, Saha S, Bansal A, Godwin AK. Extracellular vesicles as liquid biopsy biomarkers across the cancer journey: from early detection to recurrence. Clin Chem 2024;70:206-19.
11. Cheng S, Li Y, Yan H, et al. Advances in microfluidic extracellular vesicle analysis for cancer diagnostics. Lab Chip 2021;21:3219-43.
12. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018;7:1535750.
13. Jeppesen DK, Zhang Q, Franklin JL, Coffey RJ. Extracellular vesicles and nanoparticles: emerging complexities. Trends Cell Biol 2023;33:667-81.
14. Nowak M, Górczyńska J, Kołodzińska K, Rubin J, Choromańska A. Extracellular vesicles as drug transporters. Int J Mol Sci 2023;24:10267.
16. Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 2018;19:213-28.
17. Decruyenaere P, Offner F, Vandesompele J. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review. Exp Hematol Oncol 2021;10:13.
18. Ghanam J, Chetty VK, Barthel L, Reinhardt D, Hoyer PF, Thakur BK. DNA in extracellular vesicles: from evolution to its current application in health and disease. Cell Biosci 2022;12:37.
19. Malkin EZ, Bratman SV. Bioactive DNA from extracellular vesicles and particles. Cell Death Dis 2020;11:584.
20. Elzanowska J, Semira C, Costa-Silva B. DNA in extracellular vesicles: biological and clinical aspects. Mol Oncol 2021;15:1701-14.
21. Jabalee J, Towle R, Garnis C. The role of extracellular vesicles in cancer: cargo, function, and therapeutic implications. Cells 2018;7:93.
22. Kikuchi S, Yoshioka Y, Prieto-Vila M, Ochiya T. Involvement of extracellular vesicles in vascular-related functions in cancer progression and metastasis. Int J Mol Sci 2019;20:2584.
23. Bhatta B, Luz I, Krueger C, et al. Cancer cells shuttle extracellular vesicles containing oncogenic mutant p53 proteins to the tumor microenvironment. Cancers (Basel) 2021;13:2985.
24. Putz U, Mah S, Goh CP, Low LH, Howitt J, Tan SS. PTEN secretion in exosomes. Methods 2015;77-78:157-63.
25. Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol 2023;23:236-50.
26. Al-Mayah AH, Bright SJ, Bowler DA, Slijepcevic P, Goodwin E, Kadhim MA. Exosome-mediated telomere instability in human breast epithelial cancer cells after X irradiation. Radiat Res 2017;187:98-106.
27. Wang Z, Lieberman PM. The crosstalk of telomere dysfunction and inflammation through cell-free TERRA containing exosomes. RNA Biol 2016;13:690-5.
28. Terlecki-Zaniewicz L, Lämmermann I, Latreille J, et al. Small extracellular vesicles and their miRNA cargo are anti-apoptotic members of the senescence-associated secretory phenotype. Aging 2018;10:1103-32.
29. Wang J, Hendrix A, Hernot S, et al. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood 2014;124:555-66.
30. Yang L, Wu XH, Wang D, Luo CL, Chen LX. Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro. Mol Med Rep 2013;8:1272-8.
31. Federici C, Petrucci F, Caimi S, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One 2014;9:e88193.
32. Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012;227:658-67.
33. Samuel P, Mulcahy LA, Furlong F, et al. Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells. Philos Trans R Soc Lond B Biol Sci 2018;373:20170065.
34. Ferlizza E, Romaniello D, Borrelli F, et al. Extracellular vesicles and epidermal growth factor receptor activation: interplay of drivers in cancer progression. Cancers (Basel) 2023;15:2970.
35. Jacobson CA, Longo DL. Non-hodgkin’s lymphoma. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL, editors. Harrison’s Principles of Internal Medicine, 21e. New York: McGraw-Hill; 2022.
36. NIH: National Cancer Institute. Non-hodgkin lymphoma treatment (PDQ®) – health professional version. Available from: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq [Last accessed on 24 Jun 2024].
37. Parham P. The immune system. 4th ed. Garland Science: Taylor & Francis Group; 2015. p. 1-532.
38. Mount Sinai. Non-Hodgkin’s lymphoma. Available from: https://www.mountsinai.org/health-library/report/non-hodgkins-lymphoma [Last accessed on 24 Jun 2024].
39. Diffuse Large B-Cell. KUMC Panopto pathology slide tours. Available from: https://kumc.hosted.panopto.com/Panopto/Pages/Embed.aspx?pid=54880ca6-5c1e-431f-80a0-ac8d0115fce4&id=b923d9a8-a3de-4f68-b15e-ab3c0164b485 [Last accessed on 24 Jun 2024].
40. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin’s lymphoma. Med Sci 2021;9:5.
41. Navarro-Tableros V, Gomez Y, Camussi G, Brizzi MF. Extracellular vesicles: new players in lymphomas. Int J Mol Sci 2018;20:41.
42. Chu Y, Liu Y, Fang X, et al. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol 2023;13:1059914.
43. NIH: National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: non-Hodgkin lymphoma. Available from: https://seer.cancer.gov/statfacts/html/nhl.html [Last accessed on 24 Jun 2024].
44. Padala SA, Kallam A. Diffuse large B-cell lymphoma. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557796 [Last accessed on 24 Jun 2024].
45. Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 2015;15:172-84.
46. Wagener R, Lopez C, Siebert R. Pathogenesis of B-cell lymphoma. In: Abla O, Attarbaschi A, editors. Non-Hodgkin’s Lymphoma in Childhood and Adolescence. Switzerland: Springer, Cham; 2019.
47. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378:1396-407.
48. Ofori K, Bhagat G, Rai AJ. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: current state of the art and unmet clinical needs. Br J Clin Pharmacol 2021;87:284-94. [PMID: 33080045 DOI: 10.1111/bcp.14611].
49. Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol 2020;13:175.
50. NIH: National Cancer Institute: Cancer Currents Blog. Should CAR T cells be used earlier in people with non-Hodgkin lymphoma? Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2022/nhl-car-t-cells-belinda-transform-zuma7 [Last accessed on 24 Jun 2024].
51. Lai CP, Mardini O, Ericsson M, et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 2014;8:483-94.
52. Ciferri MC, Quarto R, Tasso R. Extracellular vesicles as biomarkers and therapeutic tools: from pre-clinical to clinical applications. Biology 2021;10:359.
54. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008;44:946-53.
55. Gutknecht MF, Holodick NE, Rothstein TL. B cell extracellular vesicles contain monomeric IgM that binds antigen and enters target cells. iScience 2023;26:107526.
56. Zheng D, Huo M, Li B, et al. The role of exosomes and exosomal microRNA in cardiovascular disease. Front Cell Dev Biol 2020;8:616161.
57. O'Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol 2020;21:585-606.
58. Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol 2021;32:466-77.
59. Wei Z, Batagov AO, Schinelli S, et al. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nat Commun 2017;8:1145.
60. Lai CP, Kim EY, Badr CE, et al. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun 2015;6:7029.
61. Cao D, Cao X, Jiang Y, et al. Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma. Hematol Oncol 2022;40:172-80.
62. Liu J, Han Y, Hu S, et al. Circulating exosomal MiR-107 restrains tumorigenesis in diffuse large B-cell lymphoma by targeting 14-3-3η. Front Cell Dev Biol 2021;9:667800.
63. Xiao XB, Gu Y, Sun DL, et al. Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma. Eur Rev Med Pharmacol Sci 2019;23:1620-5.
64. Feng Y, Zhong M, Zeng S, et al. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019;11:35-51.
65. Zare N, Haghjooy Javanmard S, Mehrzad V, Eskandari N, Kefayat A. Evaluation of exosomal miR-155, let-7g and let-7i levels as a potential noninvasive biomarker among refractory/relapsed patients, responsive patients and patients receiving R-CHOP. Leuk Lymphoma 2019;60:1877-89.
66. Yazdanparast S, Huang Z, Keramat S, et al. The roles of exosomal microRNAs in diffuse large B-cell lymphoma: diagnosis, prognosis, clinical application, and biomolecular mechanisms. Front Oncol 2022;12:904637.
67. Provencio M, Rodríguez M, Cantos B, et al. mRNA in exosomas as a liquid biopsy in non-Hodgkin lymphoma: a multicentric study by the Spanish lymphoma oncology group. Oncotarget 2017;8:50949-57.
68. Bang YH, Shim JH, Ryu KJ, et al. Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. J Cancer 2022;13:1388-97.
69. Rutherford SC, Fachel AA, Li S, et al. Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. Blood 2018;132:e13-23.
70. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24:679-90.
71. Hoshino A, Kim HS, Bojmar L, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 2020;182:1044-61.e18.
72. Liu H, Lu J, Dong Z, et al. Cell-of-Origin subtype prediction of diffuse large B-cell lymphoma using gene expression and proteomic data. Blood 2018;132:1712-1712.
73. Bram Ednersson S, Stern M, Fagman H, et al. Quantitative proteomics in diffuse large B-cell lymphoma patients reveal novel overexpressed proteins and potentially druggable targets in the ABC subtype. Blood 2019;134:3967-3967.
74. Carvalho AS, Baeta H, Henriques AFA, et al. Proteomic landscape of extracellular vesicles for diffuse large B-cell lymphoma subtyping. Int J Mol Sci 2021;22:11004.
75. Matthiesen R, Gameiro P, Henriques A, et al. Extracellular vesicles in diffuse large B cell lymphoma: characterization and diagnostic potential. Int J Mol Sci 2022;23:13327.
76. Oksvold MP, Kullmann A, Forfang L, et al. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells. Clin Ther 2014;36:847-862.e1.
77. Yao Y, Wei W, Sun J, et al. Proteomic analysis of exosomes derived from human lymphoma cells. Eur J Med Res 2015;20:8.
78. Cheng L, Hill AF. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov 2022;21:379-99.
79. Caivano A, Laurenzana I, De Luca L, et al. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumour Biol 2015;36:9739-52.
80. Cui M, Huang J, Zhang S, Liu Q, Liao Q, Qiu X. Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. Front Immunol 2021;12:613530.
81. Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 2015;125:3679-87.
82. Merryman RW, Redd RA, Taranto E, et al. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv 2023;7:4748-59.
83. Khodadoust MS, Olsson N, Chen B, et al. B-cell lymphomas present immunoglobulin neoantigens. Blood 2019;133:878-81.
84. Couto N, Elzanowska J, Maia J, et al. IgG+ extracellular vesicles measure therapeutic response in advanced pancreatic cancer. Cells 2022;11:2800.
85. Aung T, Chapuy B, Vogel D, et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A 2011;108:15336-41.
86. Melo Garcia L, Barabé F. Harnessing macrophages through the blockage of CD47: implications for acute myeloid leukemia. Cancers 2021;13:6258.
87. Schindler C, Collinson A, Matthews C, et al. Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency. PLoS One 2019;14:e0214545.
88. Zhu X, Hu H, Xiao Y, et al. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells. Cancer Lett 2022;536:215668.
89. Ukrainskaya VM, Musatova OE, Volkov DV, et al. CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality. Sci Rep 2023;13:463.
90. Cox MJ, Lucien F, Sakemura R, et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther 2021;29:1529-40.
91. Zhang Y, Ge T, Huang M, et al. Extracellular vesicles expressing CD19 antigen improve expansion and efficacy of CD19-targeted CAR-T cells. Int J Nanomedicine 2023;18:49-63.
92. Huang M, Zhao L, Li D, Huang L, Wang J, Zhang Y. Targeted delivery of IL-12 via CD19-modified extracellular vesicles enhances CAR-T cell efficacy against lymphoma. Blood 2023;142:6798.
93. Calvo V, Izquierdo M. T lymphocyte and CAR-T cell-derived extracellular vesicles and their applications in cancer therapy. Cells 2022;11:790.
94. Fu W, Lei C, Liu S, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun 2019;10:4355.
95. Yang P, Cao X, Cai H, et al. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol 2021;360:104262.
96. Aharon A, Horn G, Bar-Lev TH, et al. Extracellular vesicles derived from chimeric antigen receptor-t cells: a potential therapy for cancer. Hum Gene Ther 2021;32:1224-41.
97. Xu Q, Zhang Z, Zhao L, et al. Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. J Control Release 2020;326:455-67.
98. Haque S, Vaiselbuh SR. CD19 chimeric antigen receptor-exosome targets CD19 positive B-lineage acute lymphocytic leukemia and induces cytotoxicity. Cancers 2021;13:1401.
99. Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012;10:134.
100. Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin 2017;38:754-63.
101. Ferreira D, Moreira JN, Rodrigues LR. New advances in exosome-based targeted drug delivery systems. Crit Rev Oncol Hematol 2022;172:103628.
102. Pirisinu M, Pham TC, Zhang DX, Hong TN, Nguyen LT, Le MT. Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: recent advances, current obstacles, and challenges for clinical translation. Semin Cancer Biol 2022;80:340-55.
103. Goh WJ, Lee CK, Zou S, Woon EC, Czarny B, Pastorin G. Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy. Int J Nanomedicine 2017;12:2759-67.
104. Makita S, Yoshimura K, Tobinai K. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci 2017;108:1109-18.
105. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531-44.
106. Schuster SJ, Bishop MR, Tam CS, et al. JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380:45-56.
107. Yin Z, Zhang Y, Wang X. Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomark Res 2021;9:58.
108. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021;11:69.
109. Li M, Soder R, Abhyankar S, et al. WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1. J Extracell Vesicles 2021;10:e12067.
110. Miao L, Zhang Z, Ren Z, Li Y. Reactions related to CAR-T cell therapy. Front Immunol 2021;12:663201.
111. Meng X, Yu J, Fan Q, et al. Characteristics and outcomes of non-Hodgkin's lymphoma patients with leptomeningeal metastases. Int J Clin Oncol 2018;23:783-9.
112. Tang XJ, Sun XY, Huang KM, et al. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy. Oncotarget 2015;6:44179-90.
113. Hendrix A, Lippens L, Pinheiro C, et al. Extracellular vesicle analysis. Nat Rev Methods Primers 2023;3:56.
114. Steen CB, Luca BA, Esfahani MS, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 2021;39:1422-1437.e10.
115. Bram Ednersson S, Stern M, Fagman H, et al. Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients. Leuk Lymphoma 2021;62:2360-73.
116. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med 2019;25:44-56.
